Movva Sujana, Verschraegen Claire
University of New Mexico Cancer Research and Treatment Center, Division of Hematology Oncology, Albuquerque, NM 87131, USA.
Expert Opin Biol Ther. 2009 Feb;9(2):231-41. doi: 10.1517/14712590802643347.
Cytotoxic T lymphocyte antigen 4 (CTLA-4) is an inhibitory regulator of the T cell immune response against tumor cells. Ipilimumab (MDX-010) is a monoclonal antibody directed against CTLA-4.
To describe the basic mechanism of ipilimumab and discuss data available to date with regards to its safety and efficacy profile.
Data from clinical trials including abstracts were reviewed using the PubMed Database as well as the American Society of Clinical Oncology Abstract Database.
CTLA-4 inhibition with a monoclonal antibody is usually well tolerated and has efficacy as a therapeutic agent in a variety of cancers. The most clinically important toxicities have been related to autoimmune events, and guidelines for treatment of these effects are now available. Preliminary results indicate that therapy with ipilimumab leads to durable responses. Pharmacokinetics and pharmacodynamics are different from those of traditional chemotherapy agents. Phase III studies are currently underway for melanoma.
细胞毒性T淋巴细胞相关抗原4（CTLA-4）是T细胞针对肿瘤细胞免疫反应的一种抑制性调节因子。伊匹单抗（MDX-010）是一种针对CTLA-4的单克隆抗体。
描述伊匹单抗的基本作用机制，并讨论目前有关其安全性和疗效的可用数据。
使用PubMed数据库以及美国临床肿瘤学会摘要数据库对包括摘要在内的临床试验数据进行了综述。
用单克隆抗体抑制CTLA-4通常耐受性良好，并且作为治疗药物在多种癌症中具有疗效。临床上最重要的毒性反应与自身免疫事件有关，目前已有针对这些效应的治疗指南。初步结果表明，伊匹单抗治疗可产生持久反应。其药代动力学和药效动力学与传统化疗药物不同。目前正在进行黑色素瘤的III期研究。
